Sale of PerClot (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Jul. 28, 2021	May 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of non-financial assets, net			$ 0	$ 14,250	$ 0
Gain from sale of non-financial assets			0	14,250	0
Perclot revenues			388,537	354,004	313,789
Sublease income			465	278	$ 306
PerClot
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration for sale of assets	$ 41,000
Proceeds from sale of non-financial assets, net		$ 18,800
Gain from sale of non-financial assets				14,300
Perclot revenues			$ 3,300	$ 5,100
PerClot | Transfer Of PerClot Manufacturing Equipment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contingent consideration receivable	800
PerClot | Starch Medical Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contingent liability payment	4,500	$ 4,500
PerClot | Upon Our Receipt of Premarket Approval
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of non-financial assets, net	18,800
PerClot | Artivion, Inc. And Starch Medical, Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration for sale of assets	54,500
Proceeds from sale of non-financial assets, net	25,000
PerClot | Artivion, Inc. And Starch Medical, Inc. | Baxter Achievement Of Worldwide Sales
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contingent consideration receivable	$ 10,000
Contractual period	21 months
PerClot | Starch Medical Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration for sale of assets	$ 13,500
Proceeds from sale of non-financial assets, net	6,000
PerClot | Starch Medical Inc. | Baxter Achievement Of Worldwide Sales
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contingent consideration receivable	$ 3,000